Novartis Announced The Us Food And Drug Administration (Fda) Has Granted Commercial Licensure Approval For Its Durham, North California Site, A Multi-Product Gene Therapy Manufacturing Facility. This Approval Allows The State-Of-The-Art, 170,000 Square-Foot Facility To Make, Test And Release Commercial Zolgensma, As Well As Produce Gene Therapy Product For Current And Future Clinical Trials.The Clearance Of This Milestone Brings Online The Second Commercially-Licensed Manufacturing Facility For Novartis Gene Therapies, Joining The Libertyville, Ill. Site, Which Was Approved For Zolgensma (Onasemnogene Abeparvovec) Manufacturing And Distribution In 2019. The Durham Site Will Build On Novartis Gene Therapies
